Join Now!

Begin our membership application process today!

Contact Us                                                                                                        

Kena Norris
Executive Director


Priya Stemler
Director of Operations


Paresh Patel
National Sales Manager


Jennifer Jackson
Sr. Administrative Assistant
Sonia Perez Gandara
Member Relations Specialist


General Inquiries:

FDA Approves GARDASIL 9 for Prevention of Certain Head and Neck Cancers (June 2020)


CCPAPP and Merck would like to inform our members of the FDA's recent approval of an expanded indication for GARDASIL 9. The expanded indication is for the prevention of oropharyngeal and
other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. This indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial which is currently underway.

For more information, please review Merck's News Release dated June 12, 2020. You may also contact your Merck vaccine representative or the Merck Vaccines Customer Center at 877.VAX.MERCK (877.829.6372).

For assistance or further questions regarding this update, please contact CCPAPP at or by phone at 312.227.7444. CCPAPP's pricing for Gardasil 9 and other Merck vaccines can be found on the Pricing Page of our website. Members will need their username and password to access the information.

« Back












Copyright © 2020 CCPA Purchasing Partners. All rights reserved.
Web site design and development by